BRIDGE Innovation and Business Development at UMass Chan Medical School has committed nearly $2 million in funding this year for six UMass Chan Medical School investigator-led research projects that hold promise for translation to clinical application and commercialization.
Awardees were selected by internal stakeholders and the external advisory board based on scientific merit, market opportunity and commercial viability.
“These six pioneering projects showcase the translational potential UMass Chan research has for clinical application and commercialization,” said Parth Chakrabarti, MPH, MBA, executive vice chancellor for innovation and business development. “Our world-class faculty are producing new biomedical insights into genetics, medicine and human disease that have the capacity to lead to new therapeutics to patients in the clinic. That is why, over the past six years, we have committed more than $8.5 million to build a strong pipeline of cutting-edge inventions across new therapeutics and medical devices,”
The BRIDGE Fund supports critical research milestones for inventions and discoveries that have high potential to change the course of disease. BRIDGE funding mitigates external investment risk by producing key data sets that would provide an attractive entry-point for partners and investors.
